Avoro Capital Advisors LLC Immuno Gen, Inc. Transaction History

Avoro Capital Advisors LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$12.46 - $29.95 $10.9 Million - $26.2 Million	875,000 New	875,000 $25.9 Million
Q2 2020 Aug 14, 2020	SELL	$3.32 - $5.34 $6.31 Million - $10.1 Million	-1,900,000 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$2.12 - $6.8 $4.03 Million - $12.9 Million	1,900,000 New	1,900,000 $6.48 Million

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Avoro Capital Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Avoro Capital Advisors LLC with notifications on news.